GO
Loading...

AstraZeneca PLC

More

  • April 24- Zimmer Holdings Inc said on Thursday it would buy rival orthopedic products maker Biomet Inc for more than $13 billion, the latest deal in a wave of consolidations in the healthcare industry. The deal is expected to take Zimmer from the fourth-largest seller of orthopedics products to No. 2, behind Johnson& Johnson.

  • LONDON, April 24- AstraZeneca announced faster-than-expected progress of its experimental cancer drugs and plans to spin off billions of dollars of non-core assets as it staked a claim for independence following reports of bid interest from Pfizer.

  • *Tech results lift Nasdaq futures, Apple and Facebook rally. *Attention on Apple after announcing seven-for-one stock split. NEW YORK, April 24- U.S. stock index futures were higher on Thursday, with Nasdaq futures jumping more than 1 percent following a pair of blowout results from technology stalwarts Apple and Facebook.

  • European stocks rebound as M&A boosts industrial shares Thursday, 24 Apr 2014 | 4:22 AM ET

    *M&A activity boosts Alstom, Scania. LONDON, April 24- European shares resumed their upward trend on Thursday as mergers and acquisitions and a solid update from France's Schneider Electric fuelled a rally in the industrial sector.

  • LONDON, April 24- AstraZeneca highlighted progress with new cancer drugs that may revive its fortunes as it posted a 17 percent fall in core earnings per share on Thursday, reflecting patent losses on profitable older medicines.

  • Asia shares mixed on lackluster China data Wednesday, 23 Apr 2014 | 12:06 AM ET

    TOKYO— Shares were mixed in Asia on Wednesday, as weak data from China sapped upward momentum from an overnight rally on a flurry of deals in the pharmaceutical sector. Overnight, U.S. financial data and corporate earnings helped spur gains from deals by Switzerland's Novartis with Britain's GlaxoSmithKline PLC and the Eli Lilly& Co. of the U.S.

  • *Risk sentiment bolstered by gains in US, Europe. SYDNEY/ SINGAPORE, April 23- Asian stock markets were little moved on Wednesday after a Chinese manufacturing survey met expectations, but the Australian dollar plunged to a two-week low after data showed surprisingly low inflation in that country's economy.

  • SYDNEY, April 23- Asian shares crept higher on Wednesday following merger-driven gains in Europe and on Wall Street, though investors were wary in case coming figures on Chinese manufacturing again disappointed. MSCI's broadest index of Asia-Pacific shares outside Japan added 0.15 percent.

  • *Netflix results lift Wall St, deal talk buoys Europe. NEW YORK, April 22- Global equity markets rose on Tuesday, powered by solid U.S. corporate earnings and deal-making activity among European drugmakers, while the euro hovered near break-even on uncertainty whether the European Central Bank will further ease monetary policy.

  • *AstraZeneca jumps 6.3 pct on M&A talk. The STOXX Europe 600 health care index rose 3.2 percent as AstraZeneca rallied on speculation about a bid approach from U.S. major Pfizer, while a deal to swap assets boosted GlaxoSmithKline and Novartis.

  • *Novartis to buy GSK's oncology assets for $14.5 bln. The deals, which include Novartis buying GSK's cancer drugs and GSK acquiring Novartis' vaccines business, came hot on the heels of a newspaper report that AstraZeneca had turned down a $101 billion bid approach from Pfizer- a story that sent shares across the sector surging.

  • LONDON, April 22- Shares in European drugmakers received a shot in the arm on Tuesday amid a flurry of activity, with Novartis striking a multi-billion dollar deal with GlaxoSmithKline and reports U.S. giant Pfizer had approached Britain's AstraZeneca over a deal.

  • *Novartis to buy GSK's oncology assets for $14.5 bln. *Lilly to buy Novartis' animal health arm for $5.4 bln.

  • LONDON, April 22- M&A talk in the pharmaceutical sector lifted European shares on Tuesday, but failed to support the euro, which held at a two week low against the dollar on rising expectations of further policy easing by the European Central Bank.

  • M&A in pharma helps European stocks extend rally Tuesday, 22 Apr 2014 | 4:02 AM ET

    *FTSEurofirst 300 up 0.9 pct, Euro STOXX 50 up 0.7 pct. *AstraZeneca jumps 7.4 pct on M&A talk. The euro zone's blue-chip Euro STOXX 50 index added 0.7 percent, to 3,175.96 points.

  • European shares rise early, Astra surges on M&A talk Tuesday, 22 Apr 2014 | 3:13 AM ET

    PARIS, April 22- European shares rose in early trade on Tuesday, adding to last week's rally, with AstraZeneca's stock surging on merger and acquisition talk. Shares in the UK drugmaker jumped 7.8 percent after Britain's Sunday Times reported that U.S. pharmaceutical giant Pfizer has approached its British rival to propose a 60 billion pound takeover.

  • Pfizer held talks with AstraZeneca: Reports     Tuesday, 22 Apr 2014 | 12:46 AM ET

    CNBC's Catherine Boyle discusses reports that U.S. drugmaker Pfizer held informal talks with pharmaceutical firm AstraZeneca about a takeover bid.

  • Pfizer-AstraZeneca deal? Not as crazy as it sounds Monday, 21 Apr 2014 | 6:24 PM ET
    Cholesterol drugs, Crestor, left, manufactured by AstraZeneca Plc, and Lipitor, manufactured by Pfizer Inc.

    There are some solid reasons why Pfizer's reported $101 billion bid for AstraZeneca makes some sense, analysts said.

  • AstraZeneca cancer pipeline likely draw for Pfizer Monday, 21 Apr 2014 | 6:16 PM ET
    A Pfizer technician as she works at Neusentis Ltd.'s research laboratory, a unit of Pfizer Inc., in Cambridge, U.K., on Thursday, Sept. 26, 2013.

    Pfizer Inc may come back to bid for British drug company AstraZeneca Plc after its reported 60 billion pound takeover approach was rejected.

  • *Netflix climbs in extended-hours trading after results. NEW YORK, April 21- U.S. stocks advanced modestly on Monday in subdued trading as investors showed hesitation in the wake of a strong rally last week and before a slew of key earnings releases this week.

Most Popular Video

Thursday, 24 Apr 2014 | 8:49 AM ET

Today CNBC's Jim Cramer explains why he wishes his charitable trust owned shares of Caterpillar, and shares his thoughts on the government's inability to create jobs.

Thursday, 24 Apr 2014 | 8:16 AM ET

Daniel Ernst, Hudson Square Research, provides perspective on Apple's earnings and growth potential. Apple is really innovating but they haven't done it in three years, Ernst says.

Thursday, 24 Apr 2014 | 8:02 AM ET

Doug Oberhelman, Caterpillar chairman & CEO, digs deep into the company's first quarter results and shares his outlook on global sales. CAT reported EPS of $1.44 on revenues of $13.24 billion, beating on both the top and bottom line.